23:25 , Mar 2, 2018 |  BioCentury  |  Product Development

Clever pegylation pay off

Nektar Therapeutics’ clever pegylation strategy allowed it to finesse the PK and dial down the toxicity of IL-2, turning a validated but problematic immuno-oncology mechanism into a viable candidate. The approach snagged a record-breaking deal...
07:00 , Oct 6, 2014 |  BC Week In Review  |  Financial News

Cognoptix completes venture financing

Cognoptix Inc., Acton, Mass.   Business: Diagnostic, Supply/Service   Date completed: 2014-09-30   Type: Venture financing   Raised: $15 million   Investors: Alopexx Enterprises LLC; Inventages Venture Capital; Launchpad Venture Group   Note: The company said it raised over $15 million...
07:00 , Jun 13, 2013 |  BC Innovations  |  Targets & Mechanisms

PNAG: broadening infection protection

A multi-institutional team has added more than 20 pathogens to the list of known bacteria that express poly-N-acetylglucosamine, a bacterial capsule polysaccharide that provides a potentially broad-spectrum target for vaccination.1 The findings open up new...
08:00 , Jan 2, 2012 |  BC Week In Review  |  Company News

Alopexx Enterprises LLC, Provenance deal

Alopexx and Provenance formed a JV to develop and commercialize Provenance's DI-Leu16-IL2. Provenance will contribute the compound and Alopexx will contribute $8 million to the JV, which will be named Alopexx Oncology LLC....